Implementing Alfred60 AST in a clinical lab: Clinical impact on the management of septic patients and financial analysis
Sepsis is an important cause of morbidity and mortality. An accelerated microbiology diagnosis is crucial in order to reduce the time to initiate targeted antibiotic therapy. The Alfred60 system is able to provide phenotypic Antimicrobial Susceptibility Testing (AST) results within hours. This study...
Saved in:
Published in | Annales pharmaceutiques françaises Vol. 81; no. 3; p. 466 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
France
01.05.2023
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Sepsis is an important cause of morbidity and mortality. An accelerated microbiology diagnosis is crucial in order to reduce the time to initiate targeted antibiotic therapy. The Alfred60
system is able to provide phenotypic Antimicrobial Susceptibility Testing (AST) results within hours. This study has two objectives: assess the clinical impact of this technology and determine its cost-effectiveness.
During a ten-week period, all new enterobacterial or enterococcal bloodstream infection was analyzed with the Alfred60
system, in parallel with routine methods. Its impact on the clinician's therapeutic strategy was studied. In order to assess the financial and practical aspects of the method, an analysis of the extracosts and a survey of the technical staff were conducted.
Fifty-three cases of bacteriemia were included. For the Enterobacteriaceae bacteriemias, a clinical impact was shown in 18.9% of the cases (e.g, treatment modification). The financial analysis highlighted an increase in costs (+38% for Enterobacteriaceae, +50% for Enterococci), compared to the theoretical costs reported by the firm, due to the workflow and the volumes of samples used. Finally, results of the technical staff survey were favorable in terms of ease of use of the system.
In addition to its ease of use, the Alfred60
system is able to provide an AST in a record time. This study shows a real interest of the technique in the therapeutic management of patients with enterobacterial sepsis. However, its routine implementation requires an increase of the analyzed volumes as well as a 24/7 organization of the laboratory in order to be profitable. |
---|---|
AbstractList | Sepsis is an important cause of morbidity and mortality. An accelerated microbiology diagnosis is crucial in order to reduce the time to initiate targeted antibiotic therapy. The Alfred60
system is able to provide phenotypic Antimicrobial Susceptibility Testing (AST) results within hours. This study has two objectives: assess the clinical impact of this technology and determine its cost-effectiveness.
During a ten-week period, all new enterobacterial or enterococcal bloodstream infection was analyzed with the Alfred60
system, in parallel with routine methods. Its impact on the clinician's therapeutic strategy was studied. In order to assess the financial and practical aspects of the method, an analysis of the extracosts and a survey of the technical staff were conducted.
Fifty-three cases of bacteriemia were included. For the Enterobacteriaceae bacteriemias, a clinical impact was shown in 18.9% of the cases (e.g, treatment modification). The financial analysis highlighted an increase in costs (+38% for Enterobacteriaceae, +50% for Enterococci), compared to the theoretical costs reported by the firm, due to the workflow and the volumes of samples used. Finally, results of the technical staff survey were favorable in terms of ease of use of the system.
In addition to its ease of use, the Alfred60
system is able to provide an AST in a record time. This study shows a real interest of the technique in the therapeutic management of patients with enterobacterial sepsis. However, its routine implementation requires an increase of the analyzed volumes as well as a 24/7 organization of the laboratory in order to be profitable. |
Author | Hites, M Martiny, D Potvin, M Larranaga Lapique, E |
Author_xml | – sequence: 1 givenname: M surname: Potvin fullname: Potvin, M email: manon.potvin@lhub-ulb.be organization: Microbiology Department, LHUB-ULB, rue haute, 322, 1000 Brussels, Belgium. Electronic address: manon.potvin@lhub-ulb.be – sequence: 2 givenname: E surname: Larranaga Lapique fullname: Larranaga Lapique, E organization: Department of Infectious Disease, Erasme Hospital, route de Lennik, 808, 1070 Brussels, Belgium – sequence: 3 givenname: M surname: Hites fullname: Hites, M organization: Department of Infectious Disease, Erasme Hospital, route de Lennik, 808, 1070 Brussels, Belgium – sequence: 4 givenname: D surname: Martiny fullname: Martiny, D organization: Microbiology Department, LHUB-ULB, rue haute, 322, 1000 Brussels, Belgium |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36402206$$D View this record in MEDLINE/PubMed |
BookMark | eNqFjs0KwjAQhHNQrH-vIPsCQtpqQG9FFD3rvWzTVFeSbWgi6NtbRM-ehhm-GWYiBtyyGYixlDJfrtZyk4hJCPfeKZWmI5HkaiWzTKqxeJ6ct8YZjsRXKGzTmVpJKM4XIAYEbYlJowWL1RZ2P0fOo47QMsSbAYeM188ItA0E4yNp8BipTwIg19AQI2vqmz1qX4HCTAwbtMHMvzoVi8P-sjsu_aNypi59Rw67V_m7mv0F3iNSS58 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. |
Copyright_xml | – notice: Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE MEDLINE with Full Text Medline Complete PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 36402206 |
Genre | Journal Article |
GeographicLocations | Belgium |
GeographicLocations_xml | – name: Belgium |
GroupedDBID | 08J 08T 0R~ 457 53G 5GY AAEDT AALRI AAXUO AFNOS AFTJW AITUG ALMA_UNASSIGNED_HOLDINGS AOOFG CGR CUY CVF EBS ECM EIF EJD F5P FDB HZ~ NPM O9- P2P RIG SEM SES |
ID | FETCH-pubmed_primary_364022062 |
ISSN | 0003-4509 |
IngestDate | Tue Oct 29 09:21:59 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Alfred60(AST) Antibiogramme Antimicrobial susceptibility testing Bloodstream infections Hémocultures Rapid susceptibility testing Sepsis Bactériémies Antibiogramme rapide Blood cultures |
Language | English |
License | Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-pubmed_primary_364022062 |
PMID | 36402206 |
ParticipantIDs | pubmed_primary_36402206 |
PublicationCentury | 2000 |
PublicationDate | 2023-May |
PublicationDateYYYYMMDD | 2023-05-01 |
PublicationDate_xml | – month: 05 year: 2023 text: 2023-May |
PublicationDecade | 2020 |
PublicationPlace | France |
PublicationPlace_xml | – name: France |
PublicationTitle | Annales pharmaceutiques françaises |
PublicationTitleAlternate | Ann Pharm Fr |
PublicationYear | 2023 |
SSID | ssj0036611 |
Score | 4.6368985 |
Snippet | Sepsis is an important cause of morbidity and mortality. An accelerated microbiology diagnosis is crucial in order to reduce the time to initiate targeted... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 466 |
SubjectTerms | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Bacteremia - diagnosis Bacteremia - drug therapy Belgium Costs and Cost Analysis Humans Microbial Sensitivity Tests - economics Microbial Sensitivity Tests - methods Sepsis - diagnosis Sepsis - drug therapy |
Title | Implementing Alfred60 AST in a clinical lab: Clinical impact on the management of septic patients and financial analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36402206 |
Volume | 81 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa8IwEA66wfBl7PdvuYfhizo6W1u7N5GJG24Ic-CbtDVhg1mLdWPur98lMWkmE9xeSm1qaft9zV0ud18IuYxGoe-jIaq6tcjCAYrPqmHIZSvrlHpcAC8Ua0Y-PLqdZ-d-UB_kcnMja-l9Fl5FX7_WlfwHVTyGuPIq2T8gqy-KB3Af8cUtIozbtTAW0r4i34fHNt7YlI5cq9x86vMohlH1iEjzkX9L_ValkTLFcawzYLjnmPI0l0jprUoFZ6ZlOYKFhonp0woNZpqWkxcdHufGpszQDIp5eI9PT2nfvTeZfUjhAh306QbTKb-JoNwNEv7nHyUSHfSK0x_nS-2DeZawvAhb1IwkQd0V21WnbvlmV9y4NihnG_2qI5dmMTBNxgJU23V4rfAarUuy2qopT_JeQ4yb79rKhNvotOilFvk9FsiWOn9p-CHckP4O2V6MH6ApybBLcjTeI6WefPXzCvSzerq0AiXoZdLk833yaTIGFGMAGQOvMQSgGAPImBtQfAHJF5jEgHyBjC8wYSD5AoovgHwBzRdQfDkgxfZtv9WpyqcaJlLkZKiet3ZINuJJTI8JuOHIGlG0jp7Lp9MZ9t2RZYWOZ9UYs6l1Qo5WXOR0ZcsZKWTsOCebDD9NeoF-3iwsCky-ATYqWwI |
link.rule.ids | 783 |
linkProvider | Clarivate |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Implementing+Alfred60+AST+in+a+clinical+lab%3A+Clinical+impact+on+the+management+of+septic+patients+and+financial+analysis&rft.jtitle=Annales+pharmaceutiques+fran%C3%A7aises&rft.au=Potvin%2C+M&rft.au=Larranaga+Lapique%2C+E&rft.au=Hites%2C+M&rft.au=Martiny%2C+D&rft.date=2023-05-01&rft.issn=0003-4509&rft.volume=81&rft.issue=3&rft.spage=466&rft_id=info%3Apmid%2F36402206&rft_id=info%3Apmid%2F36402206&rft.externalDocID=36402206 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4509&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4509&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4509&client=summon |